ATTO Attovia Therapeutics, Inc.

Fundamentals / CIK 0002058707 / USD

Attovia Therapeutics, Inc. reported $411.8M in total assets through September 30, 2026 from SEC EDGAR filings.

Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open ATTO in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.

Financial statements and ratios

Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.

Income Statement (Annual) · Reported in USD · Newest filing period first.

No annual income statement rows are available in SEC EDGAR CompanyFacts for ATTO.

Income Statement (Quarterly) · Reported in USD · Newest filing period first.

Income Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Revenue $0 $450K -- $360K $0 --
Research & Development $20.29M $18.95M -- $12.32M $13.59M --
Total Operating Expenses $25.02M $22.25M -- $15.96M $16.62M --
Operating Income -$25.02M -$21.80M -- -$15.60M -$16.62M --
EBITDA -$24.82M -$21.60M -- -$15.40M -$16.42M --
Interest Income $2.79M $1.14M -- $1.85M $2.04M --
Net Income -$22.27M -$20.69M -$18.66M -$13.78M -$14.44M -$15.15M
Basic EPS -$0.76 -$4.88 -- -$3.44 -$3.71 --
Diluted EPS -$0.76 -$4.88 -- -$3.44 -$3.71 --
Basic Shares Outstanding 29.4M 4.2M -- 4.0M 3.9M --
Diluted Shares Outstanding 29.4M 4.2M -- 4.0M 3.9M --

Balance Sheet (Annual) · Reported in USD · Newest filing period first.

No annual balance sheet rows are available in SEC EDGAR CompanyFacts for ATTO.

Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.

Balance Sheet 2026-09-30 2026-06-30 2025-12-31
Cash & Cash Equivalents $115.4M $32.83M $40.19M
Short-Term Investments $280.6M $82.30M $112.1M
Cash & Short-Term Investments $395.9M $115.1M $152.3M
Total Current Assets $404.5M $118.4M $156.3M
Property, Plant & Equipment, Net $3.15M $3.34M $3.49M
Other Non-Current Assets $586K $2.62M $1.33M
Total Non-Current Assets $7.31M $9.95M $9.60M
Total Assets $411.8M $128.3M $165.9M
Accounts Payable $4.22M $6.00M $3.55M
Deferred Revenue (Current) $0 $0 $450K
Total Current Liabilities $11.67M $12.62M $11.01M
Other Non-Current Liabilities $672K $678K $755K
Total Non-Current Liabilities $2.41M $2.97M $4.10M
Total Liabilities $14.08M $15.58M $15.10M
Total Debt (incl. Leases) $3.84M $4.33M $5.26M
Common Stock $5.0K $1.0K $1.0K
Retained Earnings -$172.6M -$150.4M -$111.0M
Accumulated Other Comp. Income -$548K -$79K $99K
Total Stockholders' Equity $397.7M -$145.5M -$107.4M
Total Equity $397.7M -$145.5M -$107.4M

Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.

No annual cash flow statement rows are available in SEC EDGAR CompanyFacts for ATTO.

Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.

Cash Flow Statement 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Net Income -$22.27M -$20.69M -$18.66M -$13.78M -$14.44M -$15.15M
Depreciation & Amortization $200K $200K -- $200K $200K --
Stock-Based Compensation $1.63M $692K -- $679K $563K --

Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.

No annual ratios & growth rows are available in SEC EDGAR CompanyFacts for ATTO.

Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.

Ratios & Growth 2026-09-30 2026-06-30 2026-03-31 2025-09-30 2025-06-30 2025-03-31
Current Ratio 34.66x 9.39x -- -- -- --
Quick Ratio 33.93x 9.13x -- -- -- --
Debt to Equity 0.01x -- -- -- -- --
Revenue Growth (YoY) -100.0% -- -- -- -- --
Source: SEC EDGAR CompanyFacts (CIK 0002058707) · from March 31, 2025 Data through September 30, 2026 · synced Nov 20, 2026, 05:32 UTC · Open in terminal